Amount Raised
$41.5 Million
Round Type
Series B
PhiladelphiaBiotechnologyHealthcareInvestors
Description
Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round. The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In conjunction with the financing, Christopher Picariello, President, JJDC, has joined Aro’s Board of Directors.
Quick answer
Aro Biotherapeutics raised $41.5 Million in a Series B round, dated November 28, 2023. Investors: BVF Partners L.P., Christopher Picariello, President, JJDC, Healthcap, Northpond Ventures, Jjdc, Johnson & Johnson Innovation and Cowen Healthcare Investments. Aro Biotherapeutics is based in Philadelphia, Pennsylvania, United States.
- How much did Aro Biotherapeutics raise?
- Aro Biotherapeutics raised $41.5 Million in a Series B round on November 28, 2023.
- Who invested in Aro Biotherapeutics?
- BVF Partners L.P., Christopher Picariello, President, JJDC, Healthcap, Northpond Ventures, Jjdc, Johnson & Johnson Innovation and Cowen Healthcare Investments are named as investors in this round.
- What does Aro Biotherapeutics do?
- Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.
- Where is Aro Biotherapeutics based and how big is it?
- Aro Biotherapeutics is based in Philadelphia, Pennsylvania, United States. Fundz records about 49 employees.
- Who are the decision-makers at Aro Biotherapeutics?
- Fundz holds 1 contact at Aro Biotherapeutics, including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Aro Biotherapeutics, and when
A new round usually means Aro Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aro Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aro Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aro Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aro Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAro Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.